How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Movement Disorder Market
- By Disorder Type: Parkinson's Disease, Essential Tremor, Dystonia, Huntington's Disease, Tourette Syndrome
- By Treatment Type: Pharmacological Treatments, Surgical Treatments, Physical Therapy, Deep Brain Stimulation (DBS), Botulinum Toxin Therapy
- By Drug Class: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, Levodopa
- By End User: Hospitals, Neurology Clinics, Specialty Centers, Home Care Settings
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Sales
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Parkinson's Disease leads By Disorder Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.182 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.190 →
Full report · locked preview
Everything inside the Movement Disorder Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Ipsen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →UCB S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Acadia Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sunovion Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →H. Lundbeck A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Biogen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Neurocrine Biosciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Ipsen Pharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Bausch Health Companies Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Zambon Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Lundbeck
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Parkinson's Disease35.2
- Essential Tremor16.4
- Dystonia8.7
- Huntington's Disease20.5
- Tourette Syndrome19.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- AbbVie Inc.23.7
- Boston Scientific Corporation15.7
- Medtronic plc9.5
- Ipsen6.7
- Teva Pharmaceutical Industries Ltd.6.1
- UCB S.A.10.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.4
- Europe21.8
- Asia Pacific20.3
- Latin America14.4
- Middle East and Africa11.2
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | 74 | 86 | 89 | 85 | 78 | 87 | 83 |
| Boston Scientific Corporation | 93 | 75 | 79 | 76 | 80 | 93 | 83 |
| Medtronic plc | 78 | 70 | 83 | 80 | 83 | 74 | 78 |
| Ipsen | 67 | 64 | 65 | 69 | 77 | 75 | 70 |
| Teva Pharmaceutical Industries Ltd. | 51 | 59 | 63 | 54 | 58 | 52 | 56 |
| UCB S.A. | 49 | 55 | 65 | 62 | 50 | 61 | 57 |
| Acadia Pharmaceuticals Inc. | 53 | 56 | 63 | 46 | 51 | 56 | 54 |
| Sunovion Pharmaceuticals Inc. | 38 | 49 | 37 | 44 | 44 | 51 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- AbbVie Inc.
- Boston Scientific Corporation
- Medtronic plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| AbbVie Inc. | ◐ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Boston Scientific Corporation | ✓ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Medtronic plc | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Ipsen | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| Teva Pharmaceutical Industries Ltd. | ◐ | ◐ | − | ◐ | − | ◐ |
| UCB S.A. | ◐ | − | ◐ | ◐ | ◐ | ◐ |
| Acadia Pharmaceuticals Inc. | − | − | ◐ | − | − | ◐ |
| Sunovion Pharmaceuticals Inc. | − | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Challenger1
Strong scale, closing on the leaders.
Contender1
Focused players with pockets of strength.
Niche3
Specialists in a single segment or region.
Go-to-market strategy
Land Disorder Type in North America, then scale across Movement Disorder Market — a $341M beachhead inside a $5.51B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Parkinson's Disease
Best fit — highest urgency & budget in Disorder Type.
Essential Tremor
Strong fit — clear ROI and a fast path to value.
Dystonia
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disorder Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Drug Class
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Disorder Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Movement Disorder Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Movement Disorder Market is a high-growth opportunity — $5.82B by 2033, compounding at 10.2%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.2% CAGR
Demand compounds through 2033, outpacing GDP across Disorder Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disorder Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Movement Disorder Market — a $3.48B market by 2033. Plan: grow share from 9.5% to 18.8%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.5% | 18.8% | On track |
| Revenue | $326M | $653M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 32.6% | 39.1% | At risk |
| Customer retention | 85.1% | 92.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Disorder Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Treatment Type capability
A defensible second engine — invest in Treatment Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disorder Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $66M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Type
- Authorise North America expansion plan
- Fund R&D program for Disorder Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAt risk
Sales deck · value proposition
Win the Movement Disorder Market conversation — a $6.01B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disorder Type
Goal Grow share in Disorder Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Movement Disorder Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Movement Disorder Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Move-to-Earn Crypto Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportMovie Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportMoving Bed Bioreactor Market
Market size, share, segmentation and regional forecast.
$643M market · 2025 base year
View reportMoving Boxes & Shipping Supplies Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportMoving Boxes Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportMoving Column Machining Center Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportMoving Head Light Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportMoving Stairway Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportMoving Walk Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportMower Chain Saw Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportMower Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportMower-Conditioner Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy